The BCL2L11 deletion polymorphism is not associated with imatinib resistance in chronic myeloid leukemia patients: meta-analysis

被引：0
|
作者：
Xu, Jinyun [1 ,2 ]
Gu, Jiaowei [2 ]
Zhao, Yan [2 ]
Meng, Huihua [1 ]
Du, Li'an [1 ]
Zhang, Ruibo [2 ]
Jiang, Hao [2 ]
Luo, Jianming [1 ]
机构：
[1] Guangxi Med Univ, Affiliated Hosp 1, Dept Pediat, Nanning, Guangxi, Peoples R China
[2] Hubei Univ Med, Taihe Hosp, Dept Pediat, Shiyan, Hubei, Peoples R China
来源：
ONCOTARGET | 2017年 / 8卷 / 58期
关键词：
BIM; chronic myeloid leukemia; tyrosine kinase inhibitor; genetic polymorphism; drug resistance; DIAGNOSED CHRONIC-PHASE; PATIENTS RECEIVING IMATINIB; FOLLOW-UP; CYTOGENETIC RESPONSES; INTRINSIC RESISTANCE; 1ST-LINE TREATMENT; TYROSINE KINASE; BIM; DASATINIB; NILOTINIB;
D O I：
10.18632/oncotarget.21154
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
A common deletion polymorphism of the gene Bcl-2 like protein 11 (BCL2L11, BIM) has been reported to cause tyrosine kinase inhibitors (TKIs) resistance in several malignant tumors. However, the conclusions were not consistent in chronic myeloid leukemia (CML) individuals. In order to obtain a reliable conclusion, we systematically searched PubMed, Embase, Web of Science, Chinese Biomedical Database, and China National Knowledge Infrastructure and performed the meta-analysis. Six published articles contain 760 East Asian patients were identified from these electronic databases. The methodological quality of one included trial was high, and the others were moderate. Meta-analysis showed that the rate of TKI resistance between the BIM deletion and wild-type group were no statistical significance (OR = 1.24, 95% CI 0.79-1.95). In conclusion, BIM deletion may not a predictor of TKI resistance in CML individuals in East Asia.
引用
收藏
页码：99041 / 99048
页数：8
相关论文
共 50 条
  • [21] ABCB1 polymorphisms predict imatinib response in chronic myeloid leukemia patients: a systematic review and meta-analysis
    Q Zheng
    H Wu
    Q Yu
    D H (Dennis) Kim
    J H Lipton
    S Angelini
    S Soverini
    D Vivona
    N Takahashi
    J Cao
    The Pharmacogenomics Journal, 2015, 15 : 127 - 134
  • [22] The Study of SRSF1 Regulates Abnormal Alternative Splicing of BCL2L11 and the Role in Refractory Acute Myeloid Leukemia
    Wang, Qirong
    Duan, Yu
    Zan, Zhifang
    Yang, Kai
    Wang, Jinjuan
    Jia, Fengfeng
    Tan, Yanhong
    Wang, Hongwei
    Li, Li
    CHEMOTHERAPY, 2024, 69 (04) : 224 - 236
  • [23] A Common Deletion Polymorphism in the BIM Gene Contributes to Intrinsic Imatinib Resistance in Chronic Myelogenous Leukemia
    Hillmer, Axel M.
    Ng, King-Pan
    Chuah, Charles
    Juan, Wen Chun
    Ko, Tun-Kiat
    Teo, Audrey S. M.
    Ariyaratne, Pramila N.
    Takahashi, Naoto
    Sawada, Kenichi
    Fei, Yao
    Lee, Wah Heng
    Huang, Weijie
    Allen, John C., Jr.
    Woo, Xing Ti
    Nagarajan, Niranjan
    Kumar, Vikrant
    Thalamuthu, Anbupalam
    Poh, Wan Ting
    Ang, Ai Leen
    Mya, Hae Tha
    How, Gee Fung
    Yang, Li Yi
    Koh, Liang Piu
    Nadarajan, Veera S.
    Chng, Wee-Joo
    Than, Hein
    Lim, Lay Cheng
    Goh, Yeow-Tee
    Noethen, Markus M.
    Wong, Tien Y.
    Shahab, Atif
    Ruan, Xiaoan
    Cacheux-Rataboul, Valere
    Sung, Wing-Kin
    Ruan, Yijun
    Ong, S. Tiong
    BLOOD, 2011, 118 (21) : 724 - 724
  • [24] High-dose imatinib for newly diagnosed chronic phase chronic myeloid leukemia patients-Systematic review and meta-analysis
    Gafter-Gvili, Anat
    Leader, Avi
    Gurion, Ronit
    Vidal, Liat
    Ram, Ron
    Shacham-Abulafia, Adi
    Ben-Bassat, Isaac
    Lishner, Michael
    Shpilberg, Ofer
    Raanani, Pia
    AMERICAN JOURNAL OF HEMATOLOGY, 2011, 86 (08) : 657 - 662
  • [25] Comprehensive analysis of tyrosine kinase domain mutations and imatinib resistance in chronic myeloid leukemia patients
    Dhangar, Somprakash
    Shanmukhaiah, Chandrakala
    Ghatanatti, Jagdeeshwar
    Sawant, Leena
    Maurya, Nehakumari
    Vundinti, Babu Rao
    LEUKEMIA RESEARCH, 2025, 152
  • [26] Gene expression signatures associated with treatment and resistance to imatinib mesylate in chronic myeloid leukemia patients.
    Oehler, V
    Branford, S
    Pogosova-Agadjanyan, E
    Shah, N
    Sawyers, C
    Mao, M
    Linsley, P
    Hughes, T
    Radich, J
    BLOOD, 2005, 106 (11) : 131A - 131A
  • [27] Decreased Expression of microRNA-451 is Associated with Imatinib Mesylate Resistance in Chronic Myeloid Leukemia Patients
    Khalifa, Khaled
    Abbas, Omaima
    Abdlfattah, Raafat
    Alhassanin, Suzan
    Shehata, Amira
    Esawy, Sally
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S293 - S293
  • [28] MTHFR gene polymorphism and risk of myeloid leukemia: a meta-analysis
    Dong, Song
    Liu, Yueling
    Chen, Jieping
    TUMOR BIOLOGY, 2014, 35 (09) : 8913 - 8919
  • [29] TGFB2 and BCL2L11 methylation in male laryngeal cancer patients
    Shen, Zhisen
    Chen, Xiaoying
    Li, Qun
    Ye, Huadan
    Li, Jinyun
    Zhou, Chongchang
    Duan, Shiwei
    ONCOLOGY LETTERS, 2016, 12 (04) : 2999 - 3003
  • [30] Cardiovascular adverse events in chronic myeloid leukemia patients treated with nilotinib or imatinib: A systematic review, meta-analysis and integrative bioinformatics analysis
    Li, Sicong
    He, Jinshan
    Zhang, Xinyi
    Cai, Yuchun
    Liu, Jian
    Nie, Xiaoyan
    Shi, Luwen
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2022, 9
12345